Automated OCL insulin system shown to improve glucose control for youngsters at diabetes camp
New Rochelle, NY, June 7, 2016–Using an automated insulin feedback controller as part of an overnight closed-loop (OCL) control system improved glucose control (increased time within target glucose range) and reduced episodes of nocturnal hypoglycemia in children and adolescents. The design and key findings of this study, which are particularly promising because the youngsters were living in the challenging environment of a diabetes camp, are reported in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website until July 7, 2016.
Trang Ly, PhD and coauthors from Stanford University School of Medicine (CA), The University of Western Australia (Perth), and Medtronic Minimed (Northridge, CA) assessed the feasibility and effectiveness of the Medtronic Android-based PID-IFB closed-loop blood glucose control system over multiple nights. The system, intended to mimic pancreatic beta-cell function, includes an insulin pump, glucose sensor, control algorithm housed in an Android phone, and remote monitoring capabilities.
In the article “Automated Overnight Closed-Loop Control Using a Proportional-Integral-Derivative Algorithm with Insulin Feedback in Children and Adolescents with Type 1 Diabetes at Diabetes Camp,” the researchers emphasize that the level of physical activity youngsters typically engage in at diabetes camp can increase the risk for severe nocturnal hypoglycemia.
“While improving overnight glucose control, the study also found significant reductions in nocturnal hypoglycemia with the use of an automated overnight closed-loop system. This is important step to advancing towards a hybrid and/or full closed-loop system,” says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver.
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.
The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world’s leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News ), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.